MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - indian pharma
- CADILA HEALTHCARE - IPCA LABS
CADILA HEALTHCARE vs IPCA LABS - Comparison Results
CADILA HEALTHCARE Change
Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More
IPCA LABS 
Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More
Current Valuations
| CADILA HEALTHCARE | IPCA LABS | CADILA HEALTHCARE/ IPCA LABS |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 18.3 | 24.3 | 75.5% | View Chart |
| P/BV | x | 2.5 | 4.7 | 52.7% | View Chart |
| Dividend Yield | % | 1.4 | 0.3 | 539.4% |
Financials
 CADILA HEALTHCARE  IPCA LABS |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| CADILA HEALTHCARE Mar-19 |
IPCA LABS Mar-19 |
CADILA HEALTHCARE/ IPCA LABS |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 432 | 1,042 | 41.5% | |
| Low | Rs | 306 | 590 | 51.9% | |
| Sales per share (Unadj.) | Rs | 128.6 | 298.6 | 43.1% | |
| Earnings per share (Unadj.) | Rs | 18.5 | 35.0 | 53.0% | |
| Cash flow per share (Unadj.) | Rs | 24.4 | 49.4 | 49.3% | |
| Dividends per share (Unadj.) | Rs | 3.50 | 3.00 | 116.7% | |
| Dividend yield (eoy) | % | 0.9 | 0.4 | 257.7% | |
| Book value per share (Unadj.) | Rs | 101.5 | 247.1 | 41.1% | |
| Shares outstanding (eoy) | m | 1,023.74 | 126.35 | 810.2% | |
| Bonus/Rights/Conversions | - | ESOS | - | ||
| Price / Sales ratio | x | 2.9 | 2.7 | 105.1% | |
| Avg P/E ratio | x | 19.9 | 23.3 | 85.4% | |
| P/CF ratio (eoy) | x | 15.1 | 16.5 | 91.7% | |
| Price / Book Value ratio | x | 3.6 | 3.3 | 110.3% | |
| Dividend payout | % | 18.9 | 8.6 | 220.2% | |
| Avg Mkt Cap | Rs m | 378,170 | 103,108 | 366.8% | |
| No. of employees | `000 | 12.4 | 13.4 | 92.5% | |
| Total wages/salary | Rs m | 21,241 | 7,874 | 269.8% | |
| Avg. sales/employee | Rs Th | 10,585.0 | 2,807.0 | 377.1% | |
| Avg. wages/employee | Rs Th | 1,707.8 | 585.8 | 291.5% | |
| Avg. net profit/employee | Rs Th | 1,526.5 | 329.0 | 464.0% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 131,656 | 37,732 | 348.9% | |
| Other income | Rs m | 2,011 | 577 | 348.6% | |
| Total revenues | Rs m | 133,667 | 38,309 | 348.9% | |
| Gross profit | Rs m | 29,731 | 6,901 | 430.8% | |
| Depreciation | Rs m | 5,986 | 1,824 | 328.1% | |
| Interest | Rs m | 1,935 | 189 | 1,025.4% | |
| Profit before tax | Rs m | 23,821 | 5,465 | 435.9% | |
| Minority Interest | Rs m | 469 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 5,303 | 1,042 | 508.7% | |
| Profit after tax | Rs m | 18,987 | 4,422 | 429.4% | |
| Gross profit margin | % | 22.6 | 18.3 | 123.5% | |
| Effective tax rate | % | 22.3 | 19.1 | 116.7% | |
| Net profit margin | % | 14.4 | 11.7 | 123.1% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 84,981 | 23,778 | 357.4% | |
| Current liabilities | Rs m | 73,425 | 10,975 | 669.0% | |
| Net working cap to sales | % | 8.8 | 33.9 | 25.9% | |
| Current ratio | x | 1.2 | 2.2 | 53.4% | |
| Inventory Days | Days | 75 | 104 | 71.8% | |
| Debtors Days | Days | 110 | 66 | 166.1% | |
| Net fixed assets | Rs m | 133,493 | 20,368 | 655.4% | |
| Share capital | Rs m | 1,024 | 253 | 405.2% | |
| "Free" reserves | Rs m | 102,839 | 30,971 | 332.0% | |
| Net worth | Rs m | 103,863 | 31,224 | 332.6% | |
| Long term debt | Rs m | 39,497 | 1,409 | 2,804.2% | |
| Total assets | Rs m | 234,831 | 45,507 | 516.0% | |
| Interest coverage | x | 13.3 | 30.0 | 44.4% | |
| Debt to equity ratio | x | 0.4 | 0 | 843.0% | |
| Sales to assets ratio | x | 0.6 | 0.8 | 67.6% | |
| Return on assets | % | 8.9 | 10.1 | 87.9% | |
| Return on equity | % | 18.3 | 14.2 | 129.1% | |
| Return on capital | % | 18.3 | 17.3 | 105.6% | |
| Exports to sales | % | 0 | 45.9 | 0.0% | |
| Imports to sales | % | 0 | 16.6 | 0.0% | |
| Exports (fob) | Rs m | NA | 17,308 | 0.0% | |
| Imports (cif) | Rs m | NA | 6,266 | 0.0% | |
| Fx inflow | Rs m | 48,404 | 17,308 | 279.7% | |
| Fx outflow | Rs m | 11,593 | 6,266 | 185.0% | |
| Net fx | Rs m | 36,811 | 11,042 | 333.4% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 28,823 | 4,923 | 585.5% | |
| From Investments | Rs m | -57,387 | -1,563 | 3,671.4% | |
| From Financial Activity | Rs m | 18,846 | -1,832 | -1,028.7% | |
| Net Cashflow | Rs m | -7,105 | 1,528 | -465.1% | |
Share Holding
| Indian Promoters | % | 74.8 | 45.9 | 163.0% | |
| Foreign collaborators | % | 0.0 | 0.0 | - | |
| Indian inst/Mut Fund | % | 8.3 | 11.4 | 72.8% | |
| FIIs | % | 5.9 | 25.3 | 23.3% | |
| ADR/GDR | % | 0.0 | 0.0 | - | |
| Free float | % | 11.0 | 17.4 | 63.2% | |
| Shareholders | 44,069 | 36,892 | 119.5% | ||
| Pledged promoter(s) holding | % | 0.0 | 2.1 | - |
Compare CADILA HEALTHCARE With: ABBOTT INDIA JUBILANT LIFE SCIENCES BIOCON PIRAMAL ENTERPRISES NATCO PHARMA
Compare CADILA HEALTHCARE With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
|
| |
Today's Market
Sensex Ends 181 Points Higher; Energy and Healthcare Stocks Witness Buying(Closing)
Indian share markets continued to trade on a positive note during closing hours but ended their session off day's high.
Related Views on News
CADILA HEALTHCARE Announces Quarterly Results (2QFY20); Net Profit Down 79.3% (Quarterly Result Update)
Nov 15, 2019 | Updated on Nov 15, 2019For the quarter ended September 2019, CADILA HEALTHCARE has posted a net profit of Rs 829 m (down 79.3% YoY). Sales on the other hand came in at Rs 34 bn (up 13.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.
IPCA LABS Announces Quarterly Results (2QFY20); Net Profit Up 63.7% (Quarterly Result Update)
Nov 12, 2019 | Updated on Nov 12, 2019For the quarter ended September 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 63.7% YoY). Sales on the other hand came in at Rs 12 bn (up 21.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.
IPCA LABS Announces Quarterly Results (1QFY20); Net Profit Up 101.5% (Quarterly Result Update)
Aug 27, 2019 | Updated on Aug 27, 2019For the quarter ended June 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 101.5% YoY). Sales on the other hand came in at Rs 10 bn (up 18.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.
CADILA HEALTHCARE Announces Quarterly Results (1QFY20); Net Profit Down 28.9% (Quarterly Result Update)
Aug 13, 2019 | Updated on Aug 13, 2019For the quarter ended June 2019, CADILA HEALTHCARE has posted a net profit of Rs 3 bn (down 28.9% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.
IPCA LABS Announces Quarterly Results (4QFY19); Net Profit Up 113.4% (Quarterly Result Update)
Jun 3, 2019 | Updated on Jun 3, 2019For the quarter ended March 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 113.4% YoY). Sales on the other hand came in at Rs 8 bn (up 6.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.
More Views on NewsMost Popular
The Smartest Stock to Buy for 2020(Profit Hunter)
Nov 14, 2019Small-cap stocks are selling at bargain prices today and are poised to generate a lot of wealth in 2020 and beyond...
Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)
Nov 7, 2019Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?
A Trade that Could Generate Profits for Decades
Nov 14, 2019India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...
Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)
Nov 8, 2019Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.
The One Trade I'm Most Bullish on Now
Nov 12, 2019A highly specific trade to potentially triple your money in just three months. You won't find this information anywhere else!
MoreCADILA HEALTHCARE SHARE PRICE
Nov 20, 2019 (Close)
TRACK CADILA HEALTHCARE
- Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON CADILA HEALTHCARE
CADILA HEALTHCARE 8-QTR ANALYSIS
COMPARE CADILA HEALTHCARE WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.